Jasper Therapeutics, Inc. (NASDAQ:JSPR) Receives $13.14 Consensus Price Target from Analysts

Posted by on Jul 8th, 2026

Jasper Therapeutics, Inc. (NASDAQ:JSPR – Get Free Report) has earned an average rating of “Hold” from the eight brokerages that are presently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and four have assigned a buy rating to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $12.00.

Several research firms have recently commented on JSPR. UBS Group began coverage on shares of Jasper Therapeutics in a research report on Monday, March 23rd. They set a “neutral” rating for the company. Royal Bank Of Canada set a $3.00 price objective on shares of Jasper Therapeutics and gave the company a “sector perform” rating in a research report on Friday, May 15th. TD Cowen lowered shares of Jasper Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, May 15th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Jasper Therapeutics in a research report on Tuesday, April 21st.

View Our Latest Stock Analysis on JSPR

Hedge Funds Weigh In On Jasper Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in JSPR. Quadrature Capital Ltd acquired a new stake in Jasper Therapeutics in the 4th quarter valued at approximately $123,000. Millennium Management LLC boosted its position in Jasper Therapeutics by 194.2% during the 4th quarter. Millennium Management LLC now owns 1,073,783 shares of the company’s stock worth $1,965,000 after acquiring an additional 708,844 shares during the period. Engineers Gate Manager LP bought a new position in shares of Jasper Therapeutics in the fourth quarter worth $26,000. Boothbay Fund Management LLC grew its stake in shares of Jasper Therapeutics by 79.4% in the fourth quarter. Boothbay Fund Management LLC now owns 793,954 shares of the company’s stock worth $1,453,000 after purchasing an additional 351,312 shares in the last quarter. Finally, ADAR1 Capital Management LLC acquired a new position in shares of Jasper Therapeutics during the fourth quarter valued at $256,000. 79.85% of the stock is owned by institutional investors.

Jasper Therapeutics Price Performance

NASDAQ:JSPR opened at $0.48 on Friday. Jasper Therapeutics has a 12-month low of $0.32 and a 12-month high of $4.00. The firm has a market capitalization of $13.49 million, a P/E ratio of -0.15 and a beta of 3.07. The business has a 50 day simple moving average of $0.67 and a 200 day simple moving average of $1.10.

Jasper Therapeutics (NASDAQ:JSPR – Get Free Report) last issued its quarterly earnings data on Thursday, May 14th. The company reported ($0.38) EPS for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.08. Research analysts anticipate that Jasper Therapeutics will post -1.67 EPS for the current fiscal year.

Jasper Therapeutics Company Profile

(Get Free Report)

Jasper Therapeutics, Inc (NASDAQ: JSPR) is a clinical-stage biopharmaceutical company focused on translating advances in immunobiology into therapies for serious and rare diseases with unmet medical needs. The company’s research and development efforts center on engineered biologics and cell-based approaches designed to address complications in hematologic conditions and improve outcomes in transplant medicine.

Central to Jasper’s pipeline is JSP191, a monoclonal antibody targeting the CD117 receptor, which is being evaluated to enhance donor hematopoietic stem cell engraftment in patients undergoing stem cell transplantation.

Featured Articles

Analyst Recommendations for Jasper Therapeutics (NASDAQ:JSPR)

Receive News & Ratings for Jasper Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jasper Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.